6-氯-2-羟基-喹啉-3-羧酸 | 86209-35-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-氯-2-羟基-喹啉-3-羧酸
• 英文名称: 6-chloro-2-oxo-1,2-dihydroquinoline-3-carboxylic acid
• 英文别名: 6-Chloro-2-hydroxy-quinoline-3-carboxylic acid；6-chloro-2-oxo-1H-quinoline-3-carboxylic acid
• CAS: 86209-35-0
• 化学式: C₁₀H₆ClNO₃
• 分子量: 223.616
• InChiKey: XCWIXLMCHFBXLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloro-2-hydroxy-quinoline-3-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloro-2-hydroxy-quinoline-3-carboxylic acid
CAS number: 86209-35-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H6ClNO3
Molecular weight: 223.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基噻唑-5-羧酸乙酯 、 6-氯-2-羟基-喹啉-3-羧酸 在 N,N'-羰基二咪唑 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 ethyl 2-[(6-chloro-2-oxo-1H-quinoline-3-carbonyl)amino]-1,3-thiazole-5-carboxylate
  参考文献：
  名称：

  [EN] HCK INHIBITORS FOR THE TREATMENT OF FIBROSIS AND CANCER
  [FR] INHIBITEURS DE HCK POUR LE TRAITEMENT DE LA FIBROSE ET DU CANCER

  摘要：

  本发明揭示了噻唑和三唑衍生物的化合物，包括以下属的化合物：化学式I。这些化合物是造血细胞激酶（HCK）的抑制剂，具有抗纤维化和抗增殖作用。它们在治疗各种疾病中很有用，包括纤维化或纤维化疾病，如肾脏纤维化。

  公开号：

  WO2020205921A1
• 作为产物：
  描述：

  2-氨基-5-氯苯甲醛 在 乙醇 、 sodium hydroxide 、 3-哌啶甲酸乙酯 作用下， 以 乙腈 为溶剂， 反应 48.0h， 生成 6-氯-2-羟基-喹啉-3-羧酸
  参考文献：
  名称：

  [EN] HCK INHIBITORS FOR THE TREATMENT OF FIBROSIS AND CANCER
  [FR] INHIBITEURS DE HCK POUR LE TRAITEMENT DE LA FIBROSE ET DU CANCER

  摘要：

  本发明揭示了噻唑和三唑衍生物的化合物，包括以下属的化合物：化学式I。这些化合物是造血细胞激酶（HCK）的抑制剂，具有抗纤维化和抗增殖作用。它们在治疗各种疾病中很有用，包括纤维化或纤维化疾病，如肾脏纤维化。

  公开号：

  WO2020205921A1

文献信息

• [EN] GLYCINE B ANTAGONISTS<br/>[FR] ANTAGONISTES DE LA GLYCINE B
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2010037533A1

  公开（公告）日：2010-04-08

  The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

  该发明涉及喹啉衍生物及其药用盐。该发明还涉及一种制备这种化合物的方法。该发明的化合物是甘氨酸B拮抗剂，因此对于控制和预防各种疾病，包括神经系统疾病，非常有用。
• Synthesis of a boron-containing amidoxime reagent and its application to synthesize functionalized oxadiazole and quinazolinone derivatives
  作者：Bhaskar C. Das、Nitesh K. Nandwana、Devi P.Ojha、Sasmita Das、Todd Evans

  DOI：10.1016/j.tetlet.2022.153657

  日期：2022.3

  borylated amidoxime reagent for the direct synthesis of functionalized oxadiazole and quinazolinone derivatives. This reagent exhibits broad synthetic utility to obtain a variety of biologically relevant drug-like molecules. It can be easily prepared at large scale from relatively inexpensive reagents, and can undergo facile transformations to obtain target compounds. The developed amidoxime reagent

  在此，我们报道了硼化偕胺肟试剂的设计、合成和应用，用于直接合成功能化恶二唑和喹唑啉酮衍生物。该试剂具有广泛的合成用途，可用于获得多种生物学相关的药物样分子。它可以很容易地用相对便宜的试剂大规模制备，并且可以进行容易的转化以获得目标化合物。以N,N-二异丙基乙胺为碱，在乙醇中回流，由4-(4,4,5,5-四甲基-1,3,2-二氧硼杂硼烷-2-基)苯甲腈和盐酸羟胺合成了偕胺肟试剂。状况。总体优势包括生产硼化恶二唑、喹唑啉酮衍生物的无金属途径以及多步骤顺序的限制。重要的是，富含硼的药效团衍生化合物是通过有效且廉价的策略获得的。
• GLYCINE B ANTAGONIST
  申请人：Henrich Markus

  公开号：US20110190342A1

  公开（公告）日：2011-08-04

  The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

  本发明涉及喹啉衍生物及其药学上可接受的盐。本发明还涉及制备这种化合物的过程。本发明的化合物是甘氨酸B拮抗剂，因此对控制和预防各种疾病，包括神经系统疾病，非常有用。
• Sulfonylharnstoffe, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen und ihre Verwendung
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0073507A1

  公开（公告）日：1983-03-09

  Sulfonylharnstoffe der Formel in welcher bedeuten Y Alkylen mit 2-3 C-Atomen R Alkyl mit 1-4 C-Atomen R1 Wasserstoff, Chlor, Methyl R2 Alkyl mit 3-6 C-Atomen, Cycloalkyl, Alkylcycloalkyl, Cycloalkylalkyl, Cycloalkenyl, Alkylcycloalkenyl oder Cycloalkenylalkyl mit jeweils 5-8 C-Atomen und deren physiologisch verträgliche Salze, sowie Verfahren zu ihrer Herstellung und daraus hergestellte Arzneimittel.

  式中 Y 为具有 2-3 个碳原子的亚烷基 R 为具有 1-4 个碳原子的烷基 R1 为氢、氯、甲基 R2 为具有 3-6 个碳原子的烷基、环烷基、烷基环烷基、环烷基烷基、环烯基、烷基环烯基或环烯基烷基（各具有 5-8 个碳原子）及其生理容许盐的磺脲类化合物，以及其制备工艺和由此制备的药物。
• Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders
  申请人：Texas Tech University System

  公开号：US20220071953A1

  公开（公告）日：2022-03-10

  In an embodiment, the present disclosure pertains to compositions and methods for modulating cellular glucose uptake. In general, the methods include associating cells with the compositions of the present disclosure. In another aspect, the present disclosure pertains to compositions and methods to treat or prevent a disorder in a subject. The methods generally include administering the compositions of the present disclosure to the subject.